NCT07028268 A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
| NCT ID | NCT07028268 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Condition | For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2025-06-24 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 210 participants in total. It began in 2025-06-24 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors
Eligibility Criteria
Inclusion Criteria: 1. Able and willing to provide a written informed consent； 2. Male or female, ≥18 years of age； 3. Histologically or cytologically confirmed solid tumors； 4. At least 1 bone metastasis demonstrated by radiologic imaging or histopathology； 5. Eastern Cooperative Oncology Group performance Status≤2。 6. Life expectancy was judged by the investigators to be at least 6 months; 7. Adequate organ function at Screening 8. Female subjects with a negative blood pregnancy test and are not breastfeeding Exclusion Criteria: 1. Pre-existing or comorbid related oral diseases or oral cavity requiring surgery, etc； 2. History of major joint (e.g., hip, knee, or shoulder) trauma or surgery prior to the first dose of the drug； 3. Received radiotherapeutic drugs or bone radiotherapy prior to the first study drug administration 4. Any cardiovascular disease for which the investigator considers the subject unfit to participate in the study 5. resting tachycardia or resting bradycardia; 6. The subject's pain is predominantly from pain unrelated to the bone metastases; 7. Subject is unable to perform a pain assessment; 8. Symptomatic or treatment-requiring brain metastases or other central nervous system metastases 9. Comorbid infectious disease 10. Prior receipt of exogenous nerve growth factor or anti-nerve growth factor antibodies; 11. Prior history of allergy to relevant drug ingredients or components; 12. Participation in other clinical trials within a certain period of time 13. Subjects who, in the opinion of the investigator, have any other factors
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07028268 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07028268 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07028268 currently recruiting?
Yes, NCT07028268 is actively recruiting participants. Contact the research team at qian.zhao@hengrui.com for enrollment information.
Where is the NCT07028268 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07028268 clinical trial?
NCT07028268 is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. The trial plans to enroll 210 participants.